Ff

Bluebird Bio Shares Drop 20% After Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Program

Bluebird bio Inc.'s shares were sharply lower early Monday after the Food and Drug Administration pl
Bluebird Bio Shares Drop 20% After Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Program

免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

举报

评论

  • 推荐
  • 最新
empty
暂无评论